HighLife Raises $90M For US Heart Valve Study
HighLife raised more than $90 million co-led by Andera Partners and Sofinnova Partners to fund a US pivotal study of its transcatheter mitral valve system and accelerate its European commercial rollout.
Company intelligence
As of September 22, 2026, HighLife has raised at least $90M in equity across 1 sourced funding round.
Is something wrong on this page?
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Sep 22, 2026 | Growth | $90M | — | GlobeNewswirePulse story |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
HighLife has raised at least $90M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $90M Growth in September 2026, reported by GlobeNewswire. Debt financing, tender offers and secondary sales are not counted.
Lead investors in HighLife's sourced funding rounds include Andera Partners and Sofinnova Partners. Per round: its September 2026 Growth was led by Andera Partners and Sofinnova Partners.
HighLife is headquartered in Paris, France, according to sofinnovapartners.com.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.